Affordable Access

Access to the full text

Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product

Authors
  • Saleem, Ramsey1
  • Cantin, Greg1
  • Wikström, Mats1
  • Bolton, Glen1
  • Kuhns, Scott1
  • McBride, Helen J.1
  • Liu, Jennifer1
  • 1 Amgen Inc., Thousand Oaks, California, USA , Thousand Oaks (United States)
Type
Published Article
Journal
Pharmaceutical Research
Publisher
Springer-Verlag
Publication Date
May 31, 2020
Volume
37
Issue
6
Identifiers
DOI: 10.1007/s11095-020-02816-w
Source
Springer Nature
Keywords
License
Green

Abstract

PurposeABP 710 has been developed as a biosimilar to infliximab reference product (RP). The objective of this study was to assess analytical similarity (structural and functional) between ABP 710 and infliximab RP licensed by the United States Food and Drug Administration (infliximab [US]) and the European Union (infliximab [EU]), using sensitive, state-of-the-art analytical methods capable of detecting minor differences in product quality attributes.MethodsComprehensive analytical characterization utilizing orthogonal techniques was performed with 14 to 28 unique lots of ABP 710 or infliximab RP, depending on the assay. Comparisons were used to investigate the primary structure related to amino acid sequence; post-translational modifications (PTMs) including glycans; higher order structure; particles and aggregates; primary biological properties mediated by target and receptor binding; product-related substances and impurities; and general properties.ResultsABP 710 had the same amino acid sequence, primary structure, higher order structure, PTM profiles and biological activities as infliximab RP. The finished drug product had the same strength (protein content and concentration) as infliximab RP.ConclusionsBased on the comprehensive analytical similarity assessment, ABP 710 was found to be highly analytically similar to infliximab RP for all biological activities relevant for clinical efficacy and safety.

Report this publication

Statistics

Seen <100 times